Article
Oncology
Jing Si, Rong Guo, Huan Pan, Xiang Lu, Zhiqin Guo, Chao Han, Li Xue, Dan Xing, Wanxin Wu, Caiping Chen
Summary: The aim of this study was to determine whether breast cancer patients with mastectomy and false-negative frozen section in sentinel lymph node biopsy (SLNB) could forgo axillary lymph node dissection (ALND). The study found that SLNB and axillary radiation therapy could effectively replace ALND in selected patients who met specific criteria.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Ji Young You, Eun Sook Lee, Siew Kuan Lim, Youngmee Kwon, So-Youn Jung
Summary: According to the study, performing sentinel lymph node biopsy (SLNB) without axillary lymph node dissection (ALND) may be a reasonable treatment option for patients with positive lymph nodes after breast cancer surgery. There was no significant difference in the loco-regional recurrence rates between SLNB with ALND and SLNB alone.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Peiyong Li, Ciqiu Yang, Junsheng Zhang, Yitian Chen, Xiaoqi Zhang, Minting Liang, Na Huang, Yilin Chen, Kun Wang
Summary: Sentinel lymph node biopsy can provide survival results equivalent to axillary lymph node dissection for patients with cN0 and T1-2 breast cancer; however, whether it can be performed on patients with T3-4c breast cancer is still controversial.
Article
Oncology
Ian Campbell, Neil Wetzig, Owen Ung, David Espinoza, Gelareh Farshid, John Collins, James Kollias, Val Gebski, Rebecca Mister, R. John Simes, Martin R. Stockler, Grantley Gill
Summary: For early breast cancer patients who are clinically node-negative, sentinel node-based management (SNBM) is the international standard of care. In the SNAC1 study, we report the rates of axillary recurrence, overall survival, and breast cancer-specific survival at 10 years.
Article
Oncology
Isaac Cebrecos, Eduard Mension, Inmaculada Alonso, Helena Castillo, Esther Sanfeliu, Sergi Vidal-Sicart, Sergi Ganau, Maria Vidal, Francesco Schettini
Summary: In early stage breast cancer patients without lymph node metastasis, the presence of positive sentinel lymph nodes after primary systemic treatment directs axillary lymph node dissection. This study aimed to identify factors associated with non-sentinel lymph node involvement and develop a predictive score. The results showed that non-sentinel lymph node involvement was infrequent (22.2%) and associated with progesterone receptor levels and macrometastatic sentinel lymph nodes. The developed predictive score accurately predicted the absence of non-sentinel lymph node involvement, suggesting that unnecessary axillary lymph node dissection could be safely avoided in most patients.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Gilles Houvenaeghel, Monique Cohen, Pedro Raro, Jeremy De Troyer, Pierre Gimbergues, Christine Tunon de Lara, Vivien Ceccato, Veronique Vaini-Cowen, Christelle Faure-Virelizier, Frederic Marchal, Tristan Gauthier, Eva Jouve, Pierrick Theret, Claudia Regis, Philippe Gabelle, Julia Pernaut, Francesco Del Piano, Gauthier D'Halluin, Stephane Lantheaume, Emile Darai, Bassoodeo Beedassy, Caroline Dhainaut-Speyer, Xavier Martin, Sophie Girard, Richard Villet, Emilie Monrigal, Theophile Hoyek, Jean-Francois Le Brun, Pierre-Emmanuel Colombo, Agnes Tallet, Jean-Marie Boher
Summary: The study analyzed the treatment and pathological results of patients included in the SERC trial, a multicenter randomized non-inferiority phase-3 trial comparing completion axillary lymph node dissection (cALND) with sentinel lymph node biopsy alone in breast cancer patients. Patients with one or two involved sentinel nodes by micro- or macro-metastases may not require cALND, but further research is needed for those with more than two involved nodes.
Article
Oncology
Anna C. Beck, Monica Morrow
Summary: Although sentinel lymph node biopsy is the preferred method for axillary staging and therapeutic for limited nodal disease, axillary lymph node dissection is still necessary in certain cases and for maintaining local control with heavy axillary tumor burden. Knowledge of the number of involved axillary nodes, obtained through axillary lymph node dissection, is also needed for tailored systemic therapies. Ongoing trials will explore the possibility of radiotherapy as a replacement for axillary lymph node dissection in certain circumstances.
Article
Oncology
Zhao Bi, Jia-Jian Chen, Peng-Chen Liu, Peng Chen, Wei-Li Wang, Yan-Bing Liu, Chun-Jian Wang, Peng-Fei Qiu, Qing Lv, Jiong Wu, Yong-Sheng Wang
Summary: This study developed a predictive model based on a multi-center retrospective database to accurately predict whether HR+/HER2- patients can undergo genomic tests. Through multivariate logistic regression analysis, imaging abnormal nodes, the number of positive SLNs, the number of negative SLNs, pathological tumor stage, and lympho-vascular invasion were identified as independent predictors for patients having <= 3 total metastatic ALNs.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Jennifer Q. Zhang, Giacomo Montagna, Varadan Sevilimedu, Kelly Abbate, Jillian Charyn, Babak Mehrara, Monica Morrow, Andrea Barrio
Summary: This study evaluates the effect of axillary lymph node dissection (ALND) on quality of life (QOL) in breast cancer patients. The results show that QOL scores initially decrease after ALND but improve by 6 months post-surgery. Decreases in QOL were independent of arm volume. Patients with worse QOL were more likely to seek lymphedema therapy, although the effect of therapy on QOL remains unknown.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Surgery
Y. Andersson, L. Bergkvist, J. Frisell, J. de Boniface
Summary: The SENOMIC trial found that omitting axillary lymph node dissection in patients with breast cancer and sentinel node micrometastases had excellent 3-year event-free survival rates. However, patients who underwent mastectomy had worse tumor characteristics and higher risk of recurrence, especially without adjuvant radiotherapy. Long-term follow-up and enrollment of mastectomy patients are crucial.
BRITISH JOURNAL OF SURGERY
(2021)
Article
Oncology
Qiufan Zheng, Hanjia Luo, Wen Xia, Qianyi Lu, Kuikui Jiang, Ruoxi Hong, Fei Xu, Shusen Wang
Summary: This study found significant differences in overall survival and breast cancer-specific survival between SLNB and ALND, with SLNB showing a slight survival advantage.
BREAST CANCER RESEARCH AND TREATMENT
(2022)
Review
Surgery
Nur Amalina Che Bakri, Richard M. Kwasnicki, Naairah Khan, Omar Ghandour, Alice Lee, Yasmin Grant, Aleksander Dawidziuk, Ara Darzi, Hutan Ashrafian, Daniel R. Leff
Summary: This study evaluated the impact of axillary lymph node dissection (ALND) and sentinel lymph node biopsy (SLNB) on upper limb morbidity in breast cancer patients. The results showed that ALND patients had higher prevalence of lymphedema, pain, reduced strength, and range of motion compared with SLNB patients. These findings support the continued de-escalation of axillary surgery.
Article
Oncology
Matilda Appelgren, Helena Sackey, Yvonne Wengstrom, Karin Johansson, Johan Ahlgren, Yvette Andersson, Leif Bergkvist, Jan Frisell, Dan Lundstedt, Lisa Ryden, Malin Sund, Sara Alkner, Birgitte Vrou Offersen, Tove Filtenborg Tvedskov, Peer Christiansen, Jana de Boniface
Summary: This report evaluates the impact of axillary lymph node dissection (ALND) on health related quality of life (HRQoL) and patient-reported arm morbidity one year after breast cancer surgery. The study found that ALND did not have a negative impact on HRQoL and could reduce arm morbidity in patients.
Article
Oncology
Toralf Reimer
Summary: The local treatment of axilla in early breast cancer patients without clinically evident lymph node metastases is a subject of debate. Various prospective randomized surgical trials are currently being conducted to evaluate the safety of omitting sentinel lymph node biopsy in upfront breast-conserving surgery and neoadjuvant setting. These trials aim to determine whether it is possible to make therapeutic decisions without pathologic evaluation of nodal status. Additionally, ongoing trials are investigating the possibility of de-escalating surgery based on the response to neoadjuvant systemic therapy.
Article
Otorhinolaryngology
Taijiro Ozawa, Isao Oze, Takashi Matsuzuka, Eiichi Sasaki, Junkichi Yokoyama, Yoshie Sano, Masayuki Tomifuji, Koji Araki, Yasunao Kogashiwa, Ichiro Tateya, Shinya Agena, Tomohiro Sakashita, Hidenori Tsuzuki, Hoshino Terada, Hidenori Suzuki, Daisuke Nishikawa, Shintarou Beppu, Takuma Matoba, Nobuaki Mukoyama, Keisuke Oguri, Yasuhisa Hasegawa
Summary: Our study aimed to determine the indications for sentinel lymph node biopsy (SLNB), the third option for oral cancer treatment in patients with negative cervical lymph nodes. We divided the cases into three groups based on the greatest depth of invasion (DOI) and long diameter (LD) of the primary site. The proportion of SLN metastasis positivity was 21.3%, 35.3%, and 51.2% in the T1, T2, and T3 groups respectively. For certain cases in the T1 group with 2 mm < DOI ≤ 5 mm and 8 mm < LD ≤ 20 mm, the proportion of SLN metastasis positivity was 40.9%.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
(2023)
Article
Surgery
Damiano Gentile, Andrea Sagona, Erika Barbieri, Lidija Antunovic, Davide Franceschini, Agnese Losurdo, Bethania Fernandes, Corrado Tinterri
Summary: The study compared the long-term oncological outcomes of IBCR patients who had undergone either mastectomy or second BCS, showing that second BCS had significantly better DDFS, OS, and BCSS compared to salvage mastectomy.
UPDATES IN SURGERY
(2022)
Review
Surgery
Maria Lucia Mangialardi, Monica Zena, Ilaria Baldelli, Stefano Spinaci, Edoardo Raposio
Summary: Massive weight loss has positive effects on obesity-related comorbidities, but may result in excess skin, particularly breast ptosis and volume deficiency. Autologous flaps provide a solution for breast reshaping.
AESTHETIC PLASTIC SURGERY
(2022)
Article
Oncology
Marco Klinger, Agnese Losurdo, Andrea V. E. Lisa, Emanuela Morenghi, Valeriano Vinci, Fabio Corsi, Sara Albasini, Maria Cristina Leonardi, Barbara A. Jereczek-Fossa, Paolo Veronesi, Mario Rietjens, Luca Fabiocchi, Sonia Santicchia, Francesco Klinger, Andrea Loreti, Lucio Fortunato, Maria A. Bocchiotti, Fulvio A. Nicolo, Paolo Stringhini, Pier Camillo Parodi, Emanuele Rampino, Valentina Guarneri, Giulia Pagura, Erica Dalla Venezia, Graziano Meneghini, Tanja Kraljic, Paolo Persichetti, Mauro Barone, Nicola Vaia, Irene Zerini, Luca Grimaldi, Michele Riccio, Angelica Aquinati, Franco Bassetto, Vincenzo Vindigni, Luigi Ciuffreda, Corrado Tinterri, Armando Santoro
Summary: This study retrospectively analyzed early breast cancer patients and found that autologous fat grafting (AFG) did not significantly affect locoregional recurrence rate and locoregional recurrence-free survival rate compared to patients who did not undergo the procedure. The results suggest that AFG has no negative impact on cancer prognosis in early breast cancer patients.
BREAST CANCER RESEARCH AND TREATMENT
(2022)
Article
Oncology
Corrado Tinterri, Damiano Gentile, Wolfgang Gatzemeier, Andrea Sagona, Erika Barbieri, Alberto Testori, Valentina Errico, Alberto Bottini, Emilia Marrazzo, Carla Dani, Beatrice Dozin, Luca Boni, Paolo Bruzzi, Bethania Fernandes, Davide Franceschini, Ruggero Spoto, Rosalba Torrisi, Marta Scorsetti, Armando Santoro, Giuseppe Canavese
Summary: The SINODAR-ONE trial aimed to assess whether SLN biopsy only would worsen the prognosis compared with ALND in patients with T1-2 breast cancer and one or two macrometastatic SLNs. The results showed that the 3-year survival and relapse rates of patients treated with SLNB only were not inferior to those treated with ALND.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Health Care Sciences & Services
Silvia Deandrea, Francesca Ferre, Rosanna D'Antona, Catia Angiolini, Marina Bortul, Lauro Bucchi, Francesca Caumo, Lucio Fortunato, Livia Giordano, Monica Giordano, Paola Mantellini, Irene Martelli, Giuseppe Melucci, Carlo Naldoni, Eugenio Paci, Loredana Pau, Gianni Saguatti, Elisabetta Sestini, Corrado Tinterri, Milena Vainieri, Luigi Cataliotti
Summary: The survey revealed that breast centres collaborating with screening programs have higher expectations, satisfaction, and motivation for integration. Conversely, effort expectancy indicators and facilitating conditions were lower in centres not collaborating with screening programs. The results highlight the importance of integrating screening programs from the perspectives of professional career and motivation, while also identifying specific challenges that need to be addressed.
BMC HEALTH SERVICES RESEARCH
(2022)
Meeting Abstract
Oncology
Agnese Losurdo, Damiano Gentile, Monica Zuradelli, Andrea Sagona, Erika Barbieri, Monica Barile, Paolo Bianchi, Rosalba Torrisi, Wolfgang Gatzemeier, Marta Scorsetti, Corrado Tinterri, Armando Santoro
Editorial Material
Medicine, General & Internal
Matteo Lambertini, Camilla Marrocco, Stefano Spinaci, Isabelle Demeestere, Richard A. Anderson
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
(2022)
Review
Obstetrics & Gynecology
L. Arecco, E. Blondeaux, M. Bruzzone, M. Ceppi, M. M. Latocca, C. Marrocco, A. Boutros, F. Spagnolo, M. G. Razeti, D. Favero, S. Spinaci, M. Condorelli, C. Massarotti, O. Goldrat, L. Del Mastro, I Demeestere, M. Lambertini
Summary: Performing controlled ovarian stimulation (COS) before starting chemotherapy or assisted reproductive technology (ART) after completing anticancer treatment in young breast cancer patients does not seem to have a detrimental prognostic effect on breast cancer recurrence, mortality, or event-free survival (EFS).
HUMAN REPRODUCTION
(2022)
Review
Oncology
Chiara Molinelli, Flavia Jacobs, Caterina Marchio, Francesca Pitto, Maurizio Cosso, Stefano Spinaci, Evandro de Azambuja, Francesco Schettini, Elisa Agostinetto, Matteo Lambertini
Summary: There has been significant progress in the research of HER2-low breast cancer in recent years, with evidence showing that patients with this subtype can also benefit from anti-HER2 therapies. However, there are still important issues that need further investigation, including the accurate assessment of HER2-low status, clarification of its prognostic implications, and global access to newly approved drugs. This field holds great potential in providing effective personalized treatment strategies for a wider range of patients.
Review
Oncology
Maria G. Razeti, Davide Soldato, Luca Arecco, Alessia Levaggi, Silvia Puglisi, Cinzia Solinas, Elisa Agostinetto, Stefano Spinaci, Laura Lapuchesky, Carlo Genova, Claudia Massarotti, Matteo Lambertini
Summary: In patients with early breast cancer, the combination of different treatment strategies has shown significant improvements in survival outcomes. However, this comes at the cost of higher toxicity, highlighting the need for increased attention to survivorship-related issues like fertility preservation. Guidelines recommend oncofertility counseling for all reproductive-aged cancer patients, but implementation of these recommendations is suboptimal. In this review, the available evidence on oncofertility is summarized to guide healthcare providers in managing young women with breast cancer.
CLINICAL BREAST CANCER
(2023)
Article
Oncology
Corrado Tinterri, Andrea Sagona, Erika Barbieri, Simone Di Maria Grimaldi, Flavia Jacobs, Alberto Zambelli, Rubina Manuela Trimboli, Daniela Bernardi, Valeriano Vinci, Damiano Gentile
Summary: This study investigated the characteristics, treatment, and long-term outcomes of de novo metastatic breast cancer patients who received loco-regional treatment after front-line chemotherapy. The results showed that no specific subgroup of patients exhibited a statistically significant survival advantage after this treatment approach.
Article
Oncology
Davide Serrano, Sara Gandini, Parjhitham Thomas, Katherine D. Crew, Nagi B. Kumar, Lana A. Vornik, J. Jack Lee, Paolo Veronesi, Giuseppe Viale, Aliana Guerrieri-Gonzaga, Matteo Lazzeroni, Harriet Johansson, Mauro D'Amico, Flavio Guasone, Stefano Spinaci, Bjorn-Erik Bertelsen, Gunnar Mellgren, Isabelle Bedrosian, Diane Weber, Tawana Castile, Eileen Dimond, Brandy M. Heckman-Stoddard, Eva Szabo, Powel H. Brown, Andrea DeCensi, Bernardo Bonanni
Summary: This study compared different dosing schedules of exemestane, an aromatase inhibitor, in patients with breast cancer. The results showed that a 25mg dose taken three times weekly was as effective as a daily dose in decreasing serum estradiol levels, suggesting that this alternative schedule warrants further investigation.
Review
Oncology
D. Soldato, L. Arecco, E. Agostinetto, M. A. Franzoi, E. Mariamidze, S. Begijanashvili, N. Brunetti, S. Spinaci, C. Solinas, I. Vaz-Luis, A. Di Meglio, M. Lambertini
Summary: The prevalence of breast cancer survivors has been increasing steadily in the past 20 years. Early detection and breakthrough innovations in treatment strategies have contributed to the improved survival rate of breast cancer patients. However, survivors may still face challenges such as treatment side effects, psychological distress, fertility issues, and difficulties with social and work reintegration. Survivorship care should focus on addressing these specific needs and providing evidence-based strategies to improve the overall well-being of survivors.
ONCOLOGY AND THERAPY
(2023)
Article
Oncology
Damiano Gentile, Andrea Sagona, Ruggero Spoto, Davide Franceschini, Stefano Vaccari, Valeriano Vinci, Ersilia Biondi, Lorenzo Scardina, Corrado Tinterri
Summary: The study aimed to compare salvage mastectomy versus second BCS in patients with TN or HER2-enriched IBCR, showing that in some cases patients undergoing a second BCS had better distant disease-free survival, overall survival, and breast cancer-specific survival outcomes.
EUROPEAN JOURNAL OF BREAST HEALTH
(2022)
Review
Oncology
Marta Perachino, Francesca Poggio, Luca Arecco, Eva Blondeaux, Stefano Spinaci, Camilla Marrocco, Alessia Levaggi, Matteo Lambertini
Summary: Survivorship is crucial in breast cancer care, and conceiving after anticancer treatments should not be discouraged. Oncofertility counseling should be provided at diagnosis to inform patients about potential fertility issues and preservation strategies. This article focuses on pregnancy in patients with hormone receptor-positive disease and BRCA carriers.